UNSPSC 51441713: Pentetate pentasodium/stannous chloride

This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class DX201. This VA Drug Class (DX201) classifies this compound as belonging to the group IMAGING AGENTS (IN VIVO) RADIOPHARMACEUTICALS.

UNSPSC 51441713 Pentetate pentasodium/stannous chloride is a Commodity code nominally designating radiopharmaceutical compounds used in nuclear medicine imaging, but state and local recent opportunities show minimal activity aligned with that scope. The recent opportunities tagged under this code involve radiologic equipment procurement, X-ray system maintenance service plans, extended equipment warranties, and copper sulfate chemical supplies—none of which represent the radiopharmaceutical products the code name describes. State and local governments appear to be using this code to tag equipment, maintenance, and support services rather than the active pharmaceutical ingredient itself.

The issuing bodies include Maricopa County (Arizona), Escambia County Correction (Florida), Broward County Aviation Department (Florida), and Pasco County (Florida), reflecting activity across multiple county-level jurisdictions in Arizona and Florida. Representative recent opportunities include Maricopa County's IFB 362910 for radiologic equipment and installation services at three colleges (due October 22, 2026); Escambia County Correction's sole-source procurement SSCORALM2526005 for an extended warranty on X-ray machines (due August 19, 2026); and Broward County Aviation Department's RFI (posted June 25, 2026, due July 28, 2026) concerning sole-source designation for Rapiscan X-ray system maintenance services. The geographic spread concentrates in Florida and Arizona based on recent postings. Given the mismatch between the code's nominal pharmaceutical scope and the equipment and maintenance services actually being solicited, this code shows little relevant recent activity for firms pursuing radiopharmaceutical supply contracts at the state and local level.